Skip to main content
PEPTARA LABS
Get Started

Tesamorelin Research

Tesamorelin Research: What the Egrifta Trial Measured

Published by · Updated · How we research and check our pages

The short answer

Tesamorelin research rests mainly on one phase 3 trial and the FDA Egrifta label (Falutz et al., 2007; FDA Egrifta label). That randomized, placebo-controlled trial enrolled 412 adults, gave tesamorelin by subcutaneous injection at one fixed dose, and reported about a 15 percent drop in visceral adipose tissue over 26 weeks versus placebo (Falutz et al., 2007). Tesamorelin is a synthetic growth-hormone-releasing hormone (GHRH) analog sold as Egrifta, and its only FDA-approved use is reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy (FDA Egrifta label). This page reports what the study and the label describe, without the dose figures.

This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.

How did research study tesamorelin?

The studied tesamorelin plan was one fixed amount given by subcutaneous injection, the same in the pivotal trial and on the original FDA Egrifta label (Falutz et al., 2007; FDA Egrifta label).

The table below lists who was studied, the route, and what was reported. It is educational, not a prescription or a personal recommendation.

SourcePopulation studiedRouteReported outcome
Falutz et al., 2007 (NEJM)Adults with HIV-associated lipodystrophy (n=412)Subcutaneous injectionAbout 15 percent reduction in visceral adipose tissue over 26 weeks versus placebo
FDA Egrifta labelAdults with HIV-associated lipodystrophySubcutaneous injectionApproved for reducing excess visceral abdominal fat

These rows describe what researchers studied and what regulators approved. They are not instructions.

Note on formulations: the rows above reflect the original Egrifta trial and label. A later single-vial formulation (Egrifta SV) has its own, separately approved label, so the two products should not be confused.

What is tesamorelin?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) that signals the pituitary gland to release the body's own growth hormone. It reached the market under the brand name Egrifta and is the only GHRH analog with an FDA-approved indication: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy (FDA Egrifta label). The compound was tested in a randomized, placebo-controlled phase 3 trial reported by Falutz et al. in the New England Journal of Medicine in 2007 (Falutz et al., 2007; doi:10.1056/NEJMoa072375).

A tesamorelin vial calculator is published separately at peptidesvietnam.com.

How does tesamorelin work in the body?

Tesamorelin binds GHRH receptors on the pituitary and prompts a natural, pulse-like release of growth hormone, which then raises IGF-1 (Falutz et al., 2007). Because it acts upstream, it works through the body's own feedback loops rather than replacing growth hormone directly. That distinction is why researchers group it with GHRH analogs rather than with growth hormone itself.

What did the tesamorelin trial measure?

The main measure was change in visceral adipose tissue (VAT) on CT imaging, and the trial reported about a 15 percent reduction versus placebo across 26 weeks in 412 adults (Falutz et al., 2007). Researchers also tracked IGF-1, which rose in line with the drug's mechanism. The endpoint was a fat-distribution marker, not a general body-weight claim.

How does tesamorelin compare with other growth hormone secretagogues?

Tesamorelin is one of several compounds that act on the growth hormone axis, but they differ in molecule, mechanism, and evidence.

CompoundClassWhat research reportsSource
TesamorelinGHRH analogAbout 15 percent visceral fat reduction in HIV-associated lipodystrophyFalutz et al., 2007
CJC-1295GHRH analogSustained rise in growth hormone and IGF-1 after a single doseTeichman et al., 2006
IpamorelinGhrelin-type GH secretagogueSelective growth hormone release with minimal cortisol effectRaun et al., 1998
MK-677 (ibutamoren)Oral GH secretagogueHigher fasting glucose, lower insulin sensitivity in healthy older adultsNass et al., 2008

This grid compares mechanism and evidence only. It is not a dosing guide, and these compounds are not interchangeable.

What safety signals did research note?

Because tesamorelin raises growth hormone and IGF-1, studies watched blood glucose, injection-site reactions, and fluid-related effects (Falutz et al., 2007). Growth-hormone-axis compounds can influence glucose control: in a separate secretagogue, MK-677, researchers reported higher fasting glucose and lower insulin sensitivity in a randomized trial in healthy older adults (Nass et al., 2008). The FDA label carries contraindications and monitoring guidance, and any safety question belongs with a qualified clinician.

Why doesn't this page give me a personal dose?

Because the tesamorelin dose in the pivotal trial was chosen for adults with HIV-associated lipodystrophy, studied for 26 weeks under medical care, and that group is not a general reader (Falutz et al., 2007). Peptara Labs sells tesamorelin as research material for lab use, not as Egrifta, so the trial and label figures stay off this page. Health history, current medications, glucose control, and lab values all matter here, and only a qualified clinician can weigh them. For background on this class of molecules, see what are peptides.

Tesamorelin Research: FAQ

How did clinical research set the tesamorelin amount?

The pivotal trial tested one fixed dose given by subcutaneous injection for 26 weeks against placebo, and the original FDA Egrifta label draws on that trial program (Falutz et al., 2007; FDA Egrifta label). The figure is not listed here, because it was set for a patient group under medical care, not for you.

What is tesamorelin approved for?

Its only FDA-approved indication is reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy (FDA Egrifta label).

How long was the main tesamorelin trial?

The phase 3 trial by Falutz et al. ran for 26 weeks and enrolled 412 adults (Falutz et al., 2007).

How much visceral fat did tesamorelin reduce in the trial?

Researchers reported about a 15 percent reduction in visceral adipose tissue versus placebo (Falutz et al., 2007).

Is tesamorelin the same as CJC-1295 or ipamorelin?

No. All three act on the growth hormone axis, but tesamorelin and CJC-1295 are GHRH analogs while ipamorelin is a ghrelin-type secretagogue (Teichman et al., 2006; Raun et al., 1998). They are different molecules with different evidence.

Does tesamorelin affect blood sugar?

Growth-hormone-axis stimulation can influence glucose; a related oral secretagogue, MK-677, raised fasting glucose and lowered insulin sensitivity in one study (Nass et al., 2008). Discuss your own risk with a clinician.

Can I use this page to set my own dose?

No. This page reports published research and label information with no dose figure, and a qualified clinician sets any personal dose.

References

  1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375. PMID 18057338.
  2. U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection), for subcutaneous use. Full Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf
  3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
  4. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID 9849822.
  5. Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, et al. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial. Ann Intern Med. 2008;149(9):601-611. doi:10.7326/0003-4819-149-9-200811040-00003.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.

Chat with us